Patel Harita R, Pruchnicki Maria C, Hall Laura E
Shands Jacksonville, Jacksonville, FL 32209-6511, USA.
Ann Pharmacother. 2005 Jan;39(1):22-7. doi: 10.1345/aph.1E269. Epub 2004 Nov 16.
Chronic kidney disease (CKD) poses significant public health concerns. Early identification and interventions can help prevent or slow progression to end-stage renal disease.
To characterize CKD in high-risk indigent patients in a primary care setting and evaluate opportunities for pharmacists to work collaboratively with physicians to improve medication use and CKD patient outcomes.
Medical records of 200 patients with diabetes mellitus and/or hypertension were reviewed by the clinical pharmacist. Estimated glomerular filtration rate (creatinine clearance [Cl(cr)]) and urinalysis were used to identify and stage CKD according to published guidelines. Glycosylated hemoglobin concentrations and blood pressures were recorded. The pharmacist evaluated medications for possible drug-related problems (DRPs), made therapeutic recommendations, and evaluated the acceptance rate by physicians.
One hundred nineteen patients met inclusion criteria, and a total of 68.9% met CKD criteria: stage 1, 16.0%; stage 2, 20.2%; stage 3, 25.2%; stage 4, 1.7%; stage 5, 0.8%; and not stageable, 5.0%. A total of 381 DRPs were identified, averaging 3.2 (1.7) per patient (range 0-11). The number of DRPs correlated with Cl(cr) (r = -0.25; p = 0.007). Therapeutic recommendations included change of drug, dose and/or interval adjustment of the current drug, discontinuation of nonsteroidal antiinflammatory drugs, additional laboratory monitoring, meeting goal blood pressure and glycosylated hemoglobin, adding renoprotective drug and/or low-dose aspirin, and nephrologist referral. Fewer than half (40.9%) of the recommendations were accepted or accepted with modifications, and an approximately equal percentage were not accepted by the physicians.
CKD prevalence was high among the patients evaluated here. New guidelines are available to assist in managing CKD ambulatory patients. Pharmacist collaboration with physicians may optimize CKD screening in high-risk patients and improve medication usage.
慢性肾脏病(CKD)引起了重大的公共卫生关注。早期识别和干预有助于预防或减缓疾病进展至终末期肾病。
描述初级保健机构中高危贫困患者的CKD特征,并评估药剂师与医生合作改善药物使用和CKD患者结局的机会。
临床药剂师查阅了200例糖尿病和/或高血压患者的病历。根据已发表的指南,使用估计肾小球滤过率(肌酐清除率[Cl(cr)])和尿液分析来识别CKD并进行分期。记录糖化血红蛋白浓度和血压。药剂师评估药物是否存在可能的药物相关问题(DRP),提出治疗建议,并评估医生的接受率。
119例患者符合纳入标准,共有68.9%符合CKD标准:1期,16.0%;2期,20.2%;3期,25.2%;4期,1.7%;5期,0.8%;不可分期,5.0%。共识别出381个DRP,平均每位患者3.2(1.7)个(范围0 - 11)。DRP的数量与Cl(cr)相关(r = -0.25;p = 0.007)。治疗建议包括更换药物、调整当前药物的剂量和/或间隔、停用非甾体抗炎药、增加实验室监测、达到目标血压和糖化血红蛋白水平、添加肾脏保护药物和/或小剂量阿司匹林以及转诊至肾病科医生。不到一半(40.9%)的建议被接受或经修改后接受,约相同比例的建议未被医生接受。
在此评估的患者中CKD患病率较高。有新的指南可协助管理CKD门诊患者。药剂师与医生的合作可能会优化高危患者的CKD筛查并改善药物使用情况。